Exendin (10-39) removes additional N-terminal residues while preserving the main helical and C-terminal segments. The peptide allows fine dissection of residues required for initial receptor docking. Researchers employ it to evaluate how shortening the N-terminal domain affects binding affinity and conformational stability. Its truncation supports systematic exendin-based ligand engineering.
CAT No: E10007
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More